Evidence map›Paper›PMID 34381034›Full record

ArticleNature communications2021

CTCF is a barrier for 2C-like reprogramming.

Teresa Olbrich, Maria Vega-Sendino, Desiree Tillo, Wei Wu, Nicholas Zolnerowich, Raphael Pavani, Andy D Tran, Catherine N Domingo, Mariajose Franco, Marta Markiewicz-Potoczny and 7 more

Abstract read
In one paragraph

Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Exit from totipotency in mammals: an epigenetic perspective.Frontiers in cell and developmental biology · 2026
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Repetitive Sequence Stability in Embryonic Stem Cells.International journal of molecular sciences · 2024
    Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Teresa OlbrichLaboratory of Genome Integrity, CCR, NCI, NIH, Bethesda, MD, USA.
Maria Vega-SendinoLaboratory of Genome Integrity, CCR, NCI, NIH, Bethesda, MD, USA.
Desiree TilloGenetics Branch, CCR, NCI, NIH, Bethesda, MD, USA.ORCID 0000-0003-3568-6148
Wei WuLaboratory of Genome Integrity, CCR, NCI, NIH, Bethesda, MD, USA.ORCID 0000-0001-5164-2765
Nicholas ZolnerowichLaboratory of Genome Integrity, CCR, NCI, NIH, Bethesda, MD, USA.
Raphael PavaniLaboratory of Genome Integrity, CCR, NCI, NIH, Bethesda, MD, USA.
Andy D TranLaboratory of Cancer Biology and Genetics, CCR, NCI, NIH, Bethesda, MD, USA.ORCID 0000-0002-2388-7121
Catherine N DomingoLaboratory of Genome Integrity, CCR, NCI, NIH, Bethesda, MD, USA.
Mariajose FrancoLaboratory of Genome Integrity, CCR, NCI, NIH, Bethesda, MD, USA.
Marta Markiewicz-PotocznyLaboratory of Genome Integrity, CCR, NCI, NIH, Bethesda, MD, USA.ORCID 0000-0002-3586-6977
Gianluca PegoraroLaboratory of Receptor Biology and Gene Expression, CCR, NCI, NIH, Bethesda, MD, USA.
Peter C FitzGeraldGenome Analysis Unit, CCR, NCI, NIH, Bethesda, MD, USA.ORCID 0000-0001-8769-0507
Michael J KruhlakLaboratory of Cancer Biology and Genetics, CCR, NCI, NIH, Bethesda, MD, USA.
Eros Lazzerini-DenchiLaboratory of Genome Integrity, CCR, NCI, NIH, Bethesda, MD, USA.ORCID 0000-0001-5378-4644
Elphege P NoraCardiovascular Research Institute, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0002-8347-4396
André NussenzweigLaboratory of Genome Integrity, CCR, NCI, NIH, Bethesda, MD, USA.
Sergio RuizLaboratory of Genome Integrity, CCR, NCI, NIH, Bethesda, MD, USA. sergio.ruizmacias@nih.gov.ORCID 0000-0002-0177-6965

Funding

Molecular Determinants of TotipotencyZIABC011813 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI RUIZ, SERGIO · 2018 to 2025
$3.0M
Investigating the role of genome folding in transcriptional regulationR35GM142792 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI NORA, ELPHEGE-PIERRE JULIEN · 2021 to 2025
$2.0M
NIGMS NIH HHS R35 GM142792
6 · The paper itself

Abstract

Totipotent cells have the ability to generate embryonic and extra-embryonic tissues. Interestingly, a rare population of cells with totipotent-like potential, known as 2 cell (2C)-like cells, has been identified within ESC cultures. They arise from ESC and display similar features to those found in the 2C embryo. However, the molecular determinants of 2C-like conversion have not been completely elucidated. Here, we show that the CCCTC-binding factor (CTCF) is a barrier for 2C-like reprogramming. Indeed, forced conversion to a 2C-like state by the transcription factor DUX is associated with DNA damage at a subset of CTCF binding sites. Depletion of CTCF in ESC efficiently promotes spontaneous and asynchronous conversion to a 2C-like state and is reversible upon restoration of CTCF levels. This phenotypic reprogramming is specific to pluripotent cells as neural progenitor cells do not show 2C-like conversion upon CTCF-depletion. Furthermore, we show that transcriptional activation of the ZSCAN4 cluster is necessary for successful 2C-like reprogramming. In summary, we reveal an unexpected relationship between CTCF and 2C-like reprogramming.

Indexed as

Cellular ReprogrammingAnimalsBinding SitesCCCTC-Binding FactorCell DeathDNA DamageEmbryo, MammalianGene Expression Regulation, DevelopmentalHomeodomain ProteinsMiceTotipotent Stem CellsTranscription FactorsCCCTC-Binding FactorCtcf protein, mouseHomeodomain ProteinsTranscription FactorsZscan4c protein, mouse

Identifiers

PMID34381034
PMCPMC8358036

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.